Exclusive: US pharma tariffs likely weeks away as Trump plans for Alaska, sources say

The Trump administration's anticipated announcement regarding potential sector-specific tariffs on pharmaceutical imports, stemming from a Section 232 national security probe, is now expected weeks away, later than previously indicated. Global pharmaceutical companies are bracing for the outcome, which could see tariffs initially small but potentially rising to 250% on finished drugs, APIs, and raw materials. This delay, attributed to the administration's focus on other priorities, signals a significant shift in trade policy for a sector historically exempt from such measures, potentially increasing costs for U.S. consumers and conflicting with drug price reduction goals.

Analysis

The anticipated announcement of U.S. tariffs on pharmaceutical imports, stemming from a Section 232 national security investigation, has been delayed and is now expected in several weeks, a significant shift from the previously communicated timelines of mid-June and late July. This delay introduces a period of heightened uncertainty for the global pharmaceutical sector, which is bracing for potential tariffs that could start small but escalate to 250% on a wide range of products, including finished drugs and active pharmaceutical ingredients (APIs). The administration's current focus on other priorities, such as a U.S.-Russia summit and a separate national security probe into semiconductors, is cited as the reason for the postponement. This potential policy move marks a departure from the historical exemption of medical goods from trade wars and creates a direct conflict with the administration's stated goal of lowering drug prices, as tariffs would likely increase costs for U.S. consumers. While bilateral trade deals with the UK, Japan, South Korea, and the EU may offer more favorable terms for their exporters, the broader industry faces significant supply chain disruption and cost pressures, reflecting the moderately negative sentiment and uncertain tone surrounding this issue.

Key Decisions for Investors

• Investors should closely monitor White House announcements regarding the Section 232 investigations, as the timing for the pharmaceutical report is now dependent on the conclusion of the semiconductor probe.
• It is critical to assess portfolio exposure by differentiating pharmaceutical companies based on their reliance on foreign supply chains versus their domestic U.S. manufacturing footprint, as the proposed tariffs target imported APIs and finished goods.
• Consider the geographic domicile of pharmaceutical holdings, as companies in the UK, Japan, South Korea, and the EU may face more favorable terms due to bilateral agreements, potentially creating relative value opportunities compared to firms in other regions.
• The current delay provides a window to re-evaluate risk and potentially implement hedging strategies for positions in highly exposed global drugmakers, given the tail risk of tariffs as high as 250%.